Muutke küpsiste eelistusi

E-raamat: Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B

Volume editor (Ocean University of China, Qingdao, China)
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 162,44 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part BSuurem pilt
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases—30 Years Clinical Applications in China, and more.

  • Includes comprehensive coverage of molecular biology
  • Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
  • Contains contributions from renowned experts in the field
Contributors xiii
Preface xvii
1 Heparin: An essential drug for modern medicine
1(20)
Cui Hao
Hongmei Xu
Lingfan Yu
Lijuan Zhang
1 Introduction
2(1)
2 Structure of heparin
2(2)
3 The mechanisms of the heparin
4(3)
4 Clinical studies of heparin
7(4)
5 Concluding remarks
11(10)
Acknowledgments
13(1)
References
13(8)
2 Low molecular weight heparins and their clinical applications
21(20)
Cui Hao
Mojian Sun
Hongmei Wang
Lijuan Zhang
Wei Wang
1 Introduction
22(1)
2 Structure of LMWHs
23(2)
3 Clinical uses of LMWHs
25(2)
4 Update on the LMWHs under clinic trials and its potential applications
27(5)
5 Concluding remarks
32(9)
Acknowledgments
33(1)
References
34(7)
3 The clinical use of Fondaparinux: A synthetic heparin pentasaccharide
41(14)
Yiran Zhang
Meng Zhang
Lijuan Tan
Nana Pan
Lijuan Zhang
1 Structure and mechanism of Fondaparinux
42(2)
2 Pharmacokinetics and pharmacodynamics of Fondaparinux
44(2)
3 Clinical application of Fondaparinux
46(3)
4 Concluding remarks
49(6)
Acknowledgments
49(1)
Conflict of interest
49(1)
References
50(5)
4 Heparinoids Danaparoid and Sulodexide as clinically used drugs
55(20)
Huaiqian Dou
Aiqin Song
Shaoyou Jia
Lijuan Zhang
1 Heparin and heparinoids
56(3)
2 Heparin, low molecular weight heparin, Danaparoid and Sulodexide
59(2)
3 Clinical applications of Danaparoid
61(3)
4 Clinical applications of Sulodexide
64(3)
5 Concluding remarks
67(8)
Acknowledgments
68(1)
References
68(7)
5 Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond---A review of 31 years clinical experiences in China
75(20)
Ming Shan
Ningchuan Feng
Lijuan Zhang
1 Introduction
76(1)
2 Preparation, chemical structure, and clinical doses
77(1)
3 Clinical uses and efficacy
78(3)
4 Adverse reactions
81(1)
5 Pharmacodynamics
82(4)
6 Pharmacokinetics
86(1)
7 Future perspectives
86(9)
Acknowledgment
87(1)
Conflicts of interest
87(1)
References
87(8)
6 Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies
95(18)
Jing Wang
Lihua Geng
Yang Yue
Quanbin Zhang
1 Introduction
96(1)
2 Preparation and structure of fucoidan
97(2)
3 Pharmacology and mechanism of fucoidan
99(4)
4 Clinical uses and efficacy of fucoidan
103(3)
5 Future perspectives
106(7)
Acknowledgments
106(1)
References
107(6)
7 Marine glycan-derived therapeutics in China
113(22)
Yanyun Gao
Lijuan Zhang
Wenjie Jiao
1 Introduction
114(2)
2 Fucoidan (Haikunshenxi capsules)
116(1)
3 Chitin ester (PS916)
117(2)
4 Alginate-derived drugs (PSS, PGMS, 911, PGS, GV971, and HS203)
119(8)
5 Conclusions
127(8)
Acknowledgments
128(1)
Conflicts of interest
128(1)
References
128(6)
Further reading
134(1)
8 An overview of fungal glycan-based therapeutics
135(30)
Dandan Yang
Zijing Zhou
Lijuan Zhang
1 Introduction
136(1)
2 Structural studies of fugal glycans
136(4)
3 Fungal glycans-based therapeutics
140(13)
4 Future perspectives
153(12)
Acknowledgments
153(1)
Conflict of interest
153(1)
References
154(11)
9 Ganoderma sinense polysaccharide: An adjunctive drug used for cancer treatment
165(14)
Yiran Zhang
Yifei Jiang
Meng Zhang
Lijuan Zhang
1 Introduction
166(1)
2 Structure of G. sinense polysaccharides
166(1)
3 Biological function and clinical practice of G. sinense polysaccharides
167(6)
4 Discussions and conclusion
173(6)
Aknowledgement
174(1)
Conflicts of interest
174(1)
References
174(5)
10 Ganoderma lucidum polysaccharide used for treating physical frailty in China
179(42)
Pengjiao Zeng
Yulong Chen
Lijuan Zhang
Maoqing Xing
1 Introduction
181(1)
2 Structure of GLPS
182(1)
3 Ganoderma lucidum-based drugs approved by SFDA in China
183(3)
4 Immunomodulatory and anti-tumor mechanism of GLPS
186(2)
5 Biological activities of GLPS
188(18)
6 Pre- and clinical studies of GLPS
206(8)
7 Concluding remarks
214(7)
Acknowledgment
214(1)
Conflicts of interest
214(1)
References
215(4)
Further reading
219(2)
11 The biological activities of the antitumor drug Grifola frondosa polysaccharide
221(42)
Yanli He
Lijuan Zhang
Hua Wang
1 Introduction
223(1)
2 The pharmacological effects of GFP
224(30)
3 Toxicological experiments
254(1)
4 Conclusion
255(8)
Acknowledgment
255(1)
Conflicts of interest
255(1)
References
255(8)
12 Molecular basis for Porta cocos mushroom polysaccharide used as an antitumor drug in China
263(34)
Xiulian Li
Lina Ma
Lijuan Zhang
1 Introduction
265(3)
2 Pharmacological activities of PCP
268(18)
3 Clinical efficacy of PCP
286(6)
4 Toxicity
292(1)
5 Future perspectives
292(5)
Acknowledgment
293(1)
Conflict of interest
293(1)
References
293(4)
13 Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China
297(32)
Meng Zhang
Yiran Zhang
Lijuan Zhang
Qingwu Tian
1 Introduction
299(1)
2 Structure of lentinan
300(3)
3 Biological mechanisms of lentinan
303(1)
4 Preclinical and clinical studies of lentinan
303(15)
5 Concluding remarks
318(11)
Acknowledgments
319(1)
Conflicts of interest
319(1)
References
319(10)
14 The efficacy of Polyporus Umbellatus polysaccharide in treating hepatitis B in China
329(32)
Zhihua Guo
Yunjin Zang
Lijuan Zhang
1 Introduction
331(1)
2 Clinical trials on chronic hepatitis B and the underlying molecular mechanisms
332(18)
3 The anti-tumor and immuno-enhancing effect of PUPS in lung and liver cancer patients
350(1)
4 Adverse reaction of PUPS
350(1)
5 Conclusion and future perspectives
350(11)
Acknowledgments
354(1)
Conflicts of interest
354(1)
References
354(7)
15 Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China
361(22)
Huaiqian Dou
Yajing Chang
Lijuan Zhang
1 Introduction
362(5)
2 Structure of PSP
367(2)
3 Immunomodulatory and antitumor activities of PSP
369(7)
4 Toxicity and side effects of PSP
376(1)
5 Conclusions and future perspectives
377(6)
Acknowledgements
377(1)
Conflicts of interest
377(1)
References
377(6)
16 Tremella polysaccharide: The molecular mechanisms of its drug action
383(40)
Dandan Yang
Yong Liu
Lijuan Zhang
1 Introduction
385(1)
2 Structure of TFPS
386(1)
3 TFPS-based drugs approved by SFDA in China
387(1)
4 Pharmacological activities and mechanisms of TFPS
388(22)
5 Clinical studies of TFPS
410(5)
6 Future perspectives
415(8)
Acknowledgments
415(1)
Conflicts of interest
415(1)
References
415(8)
17 The structures and biological functions of polysaccharides from traditional Chinese herbs
423(22)
Pengjiao Zeng
Juan Li
Yulong Chen
Lijuan Zhang
1 Introduction
424(1)
2 Extraction, separation, purification and structural analysis method of polysaccharide
425(3)
3 Overview of biological activities of polysaccharides purified from traditional Chinese herbs
428(6)
4 Future perspectives
434(11)
Acknowledgments
438(1)
Conflict of interest
438(1)
References
438(7)
18 Biological mechanisms of glycan- and glycosaminoglycan-based nutraceuticals
445(26)
Yang Tang
Yidi Cui
Ariane De Agostini
Lijuan Zhang
1 Introduction
446(1)
2 Terrestrial sources of nutraceutical glycans
447(8)
3 Marine sources of nutraceutical glycans
455(1)
4 Discussions and conclusions
456(15)
Acknowledgments
462(1)
Conflict of interest
462(1)
References
462(9)
19 Glycosylation-dependent antitumor therapeutic monoclonal antibodies
471(16)
Yiran Zhang
Chun Fan
Lijuan Zhang
Xuexiao Ma
1 Structures of immunoglobulin
472(1)
2 Glycosylation of IgG and its significance
473(4)
3 Production of therapeutic monoclonal antibodies
477(1)
4 FDA approved antitumor therapeutic monoclonal antibodies
478(2)
5 Conclusions and perspectives
480(7)
Acknowledgments
481(1)
Conflict of interest
481(1)
References
481(6)
20 Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs
487(36)
Jing Fu
Zhongyuan Wu
Lijuan Zhang
1 Introduction
488(1)
2 Glycosylated low molecular weight drugs (GLMWDs)
489(23)
3 Conclusions and perspectives
512(11)
Acknowledgments
513(1)
Conflicts of interest
513(1)
References
513(10)
Index 523
Lijuan Zhang is a Professor of Translational Medicine at Ocean University of China. She completed her doctorates of biochemistry and molecular genetics at University of Alabama at Birmingham in 1995. Before then, she was a Fogarty International Fellow at NIH for three years studying glycan-based cancer biomarkers. She worked as post-doctorate fellow and research associate at both MIT and Harvard Medical School from 1995-2002. She joined the faculty of the Department of Pathology & Immunology at Washington University in St. Louis in 2002 as a tenure-tracked Assistant Professor. Her research had been focused on the biosynthesis, structures, and biological functions of glycans since 1985. Now her work is on translational aspects of glycans as biomarkers and therapeutics. She has over 60 peer reviewed publications. She edited and published a book entitled Glycosaminoglycans in Development, Health, and Diseases” with the contributions of top scientists worldwide in 2010 by Elsevier.
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97801281774192e.html
Märksõnad: